Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Traws Pharma (TRAW) Receivables - Other (2016 - 2019)

Traws Pharma (TRAW) has disclosed Receivables - Other for 5 consecutive years, with $35000.0 as the latest value for Q2 2019.

  • For Q2 2019, Receivables - Other changed N/A year-over-year to $35000.0; the TTM value through Jun 2019 reached $35000.0, changed N/A, while the annual FY2018 figure was $35000.0, N/A changed from the prior year.
  • Receivables - Other hit $35000.0 in Q2 2019 for Traws Pharma, roughly flat from $35000.0 in the prior quarter.
  • Across five years, Receivables - Other topped out at $2.1 million in Q2 2016 and bottomed at $31000.0 in Q4 2016.
  • Average Receivables - Other over 4 years is $763375.0, with a median of $507500.0 recorded in 2016.
  • Year-over-year, Receivables - Other soared 948.48% in 2015 and then crashed 97.76% in 2016.
  • Traws Pharma's Receivables - Other stood at $1.4 million in 2015, then plummeted by 97.76% to $31000.0 in 2016, then rose by 12.9% to $35000.0 in 2018, then changed by 0.0% to $35000.0 in 2019.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $35000.0, $35000.0, and $31000.0 for Q2 2019, Q4 2018, and Q4 2016 respectively.